No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin ; volume:11 ; number:1 ; day:1 ; month:8 ; year:2011 ; pages:1 ; date:12.2011
BMC pharmacology ; 11, Heft 1 (1.8.2011), 1, 12.2011
- Creator
-
Frey, Reiner
Mück, Wolfgang
Unger, Sigrun
Reber, Michael
Krätzschmar, Jörn
Becker, Corina
Wensing, Georg
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-11-S1-P25
- URN
-
urn:nbn:de:101:1-2019073119000635328966
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Frey, Reiner
- Mück, Wolfgang
- Unger, Sigrun
- Reber, Michael
- Krätzschmar, Jörn
- Becker, Corina
- Wensing, Georg
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial